Objective: Our previous studies have demonstrated that standard treatment of diabetes does not cause significant improvement in NAFLD. Therefore, the present study was conducted to evaluate the effects of Liraglutide-degludec fixed dose combination (FDC) 3.6mg/100 IU on NAFLD with elevated transaminases among patients with T2D. This combination has recently been available in our country.
Material and Methods: A total of 34 patients (male-13, female-21) with age group of 35-65 years, uncontrolled with oral anti diabetic drugs and basal insulin were included in the study. These patients had elevated transaminases and NAFLD. Liraglutide-degludec FDC was given along with other oral antidiabetic drugs and standard care. Selected clinical and demographic profile and liver fat content were recorded for all patients at both baseline and 24 weeks of treatment. The hepatic steatosis was assessed using transient elastography (Fibroscan) as CAP value and MR fat quantification. Age, BMI, diabetes duration, FPG, PPG, HbA1c, lipid profile, Microalbuminuria, RFT and LFT were also measured at baseline and every 3 months. All adverse events were recorded.
Parameters Baseline Week 24 Change
HbA1c (%) 8.6±0.9 7.2±0.6 -1.4%
Liver fat content (dB/m) 346.4±38.2 208.3±24 -138.1
Reversibility of transaminases 34/34 27/34 82%
Weight (kg) 84.3±8.6 79.1±6.7 -5.2
1. Liraglutide-degludec FDC is effective for reducing hyperglycemia in uncontrolled diabetes
2. It also reduces hepatic steatosis and effectively cause reversal of elevated transaminases as well as weight reduction
3.We recommend liver histology study for efficacy of this FDC in NASH treatment in T2DM